12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million.
uniQure (NASDAQ:QURE) sharesread more...
Benzinga
More News
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Zacks
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
Zacks
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
Zacks
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
Zacks
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.